Moffitt Cancer Center | Strategic Alliance Partners

February 21, 2023

A comprehensive look at the role of bispecific antibodies, including glofitamab, in the treatment of mantle cell lymphoma.

February 21, 2023

Bijal D. Shah, MD, and Matthew J. Matasar, MD, discuss how they approach treating patients with MCL who rapidly progress on BTK inhibitors.

February 16, 2023

Shared insight from Amod Sarnaik, MD, and Krishna Komanduri, MD, on the halted DELTA-1 clinical trial of ITIL-168 in melanoma, followed by a focused discussion of SITC 2022 data on emerging TIL design and manufacturing strategies.

February 16, 2023

Expert perspectives on results from C-144-01, which utilized the TIL therapy lifileucel in the setting of metastatic melanoma, and situations in which the regimen might be used in clinical practice.

February 15, 2023

Andrew Kuykendall, MD, discusses the investigation of navitoclax plus ruxolitinib in myelofibrosis.

February 15, 2023

Ricardo Costa, MD, MSC, discusses the implications of the phase 3 KEYNOTE-522 trial trial in patients with high-risk, early-stage triple-negative breast cancer.

February 15, 2023

Amer Zeidan, MBBS, and Rami Komrokji, MD, offer closing remarks on recent advances in MF and MDS, and look towards the future of treatment.

February 14, 2023

A panel of experts in hematologic malignancies analyze clinical studies and real-world data of brexucabtagene autoleucel in mantle cell lymphoma.

February 14, 2023

Alexey V. Danilov, MD, PhD, presents a second patient profile of a 60-year-old patient with MCL, and the panel discusses using CAR T-cell therapy to treat MCL.

February 10, 2023

Rutika Mehta, MD, MPH, discusses which patients with esophageal squamous cell carcinoma may benefit most from the different frontline treatment options available and highlights key treatment developments with adjuvant immunotherapy plus chemotherapy.

February 09, 2023

A focused discussion on clinical trial data presented at SITC 2022 elucidating the biologic activity of tumor-infiltrating lymphocyte therapies.

February 08, 2023

Dr Komrokji summarizes the remaining unmet needs in the treatment of MF, including suboptimal responses to JAK2 inhibitors, and comments on data from ongoing trials that may address these needs.

February 08, 2023

A comprehensive review of the treatment landscape for myelofibrosis (MF) and recent ASCO and ASH data updates on JAK2 inhibitors.

February 07, 2023

A comprehensive discussion on ways to approach treating patients with high-risk mantle cell lymphoma.

February 07, 2023

A detailed look at how to select the appropriate BTK inhibitor to treat patients with MCL and the potential role of the non-covalent BTK inhibitor pirtobrutinib in MCL.

February 03, 2023

Andrew Kuykendall, MD, discusses the evaluation of momelotinib in patients with symptomatic and anemic myelofibrosis.

February 02, 2023

Shared insight on the benefits and drawbacks of using tumor-infiltrating lymphocyte therapy for treatment of solid tumors, as compared to chimeric antigen receptor (CAR) T-cell therapy.

February 02, 2023

Expert perspectives on the mechanism of action behind tumor-infiltrating lymphocyte (TIL) therapy and how it might address existing unmet needs in the treatment of solid tumors, including melanoma and non–small cell lung cancer.

February 01, 2023

Ricardo Costa, MD, MSC, discusses the use of neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab monotherapy, in patients with high-risk, early-stage triple-negative breast cancer.

February 01, 2023

Experts in hematology take a detailed look at new data on investigational therapies for higher-risk MDS, including the STIMULUS-MDS1 trial on sabatolimab.